Bydureon exenatide or Byetta exenatide are novel GLP-1 (Glucagon-like Peptide-1) incretin mimetic hormone FDA approved for use in type 2 diabetes treatment. Byetta (exenatide) and Bydureon (exenatide) are used in combination therapy to improve blood glucose control in people diagnosed with type 2 diabetes who are taking sulfonylureas, a metformin, a thiazolidinediones (TZDs), a combination of metformin and thiazolidinediones, or a combination of sulfonylureas and metformin.
Tag Archives: Bydureon exenatide
Excessive food intake in patients with diabetes disease who are unable to reach normal body blood sugar level is thought to result in the production of incretin-antagonist hormones, leading to glucose intolerance and dysregulated insulin production in the pancreas. How to control blood sugar level. To control sugar level in blood body need to produce enough insulin to utilize excessive sugar. What is glucagon like peptide 1? Incretin hormones, such as glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide are hormones released from the small intestines in response to ingested food. Control of blood glucose levels works through join forces of insulin and glucagon like peptide 1 hormones.